Overall verdict
Neutral
5.7/10
1-year performance
+26.49%
Score breakdown
Up 26.5% over 1 year, 84% of the 52-week range.
Strongest: Financial strength 8.0/10. Weakest: Shareholder return 1.3/10.
32 analysts, target +0.1% vs the price.
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older ;
ALYFTREK for the treatment for people with CF 6 years of age and older ; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older ; ORKAMBI for CF patients 1 year or older ; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT ; JOURNAVX for the treatment of acute pain in adults ;
VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial ; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial ; VX-264 for treating Type 1 Diabetes ; VX-670 for the treatment of myotonic dystrophy type 1 ; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease.
In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
Sector
Health Care
Industry
Biotechnology
Primary listing
Nasdaq
United States
CEO
Reshma Kewalramani
Founded
1989
Employees
6 400
Revenue / employee
1.9M USD
Next earnings
February 8, 2027 (estimated)
Institutional holders
- GEODE CAPITAL MANAGEMENT, LLC2.40%
- Bank of New York Mellon Corp0.67%
- FMR LLC0.61%
- Rest of the register96.33%
3 13F filings as of September 30, 2026: US managers above $100M, filed up to 45 days after quarter end. No insiders, no retail. A share on loan is declared by its lender and by whoever bought it from the short seller, so the total can exceed 100%.
Research uses the underlying stock’s market history. The purchase quote is calculated separately when you review your order.
52-week high
568.67 USD
52-week low
412.27 USD
1-year performance
26.49%
Rising
Year-to-date performance
19.63%
Rising
Drawdown
-4.42%
Near its high
Position in the 52-week range
84% of range
Against the world ETF
Over 26 years, from December 2000 to October 2026, the share did not clearly beat the world ETF once risk is accounted for. It earned more, but shaking 3.0 times harder: once that risk is counted, it did about as well as the ETF.
$10,000 placed at the end of December 2000 are worth today
| Vertex | $78,165 |
| World ETF | $65,117 |
| S&P 500 | $91,204 |
| Risk-free placement | $15,894 |
The risk
- Shaking:the share moves 3.0 times as much as the world ETF.
- Worst fall:-88Â % between December 2000 and April 2004. $10,000 placed at the top fell to $1,208. The world ETF, at worst: -53Â %. Back to its high in 108 months.
Vertex earned more than the world ETF since 2000
Value of $10,000 placed at the end of December 2000, dividends reinvested, in dollars
- Vertex: $78,165
- World ETF: $65,117
- S&P 500: $91,204
- Risk-free placement: $15,894
Based on past performance. This is not a recommendation.
Range: 350.00 USD - 366.52 USD (3 methods agree)
The price implies growth of 15.03% per year; the company grows at 8.28%.
Gross margin 85.6%, net margin 30.5%, ROIC 17.5%, ROE 20.8%.
Net margin
30.53%
Exceptional
Sector -14.06%|S&P 13.40%
Gross margin
85.61%
Fair
Return on equity (ROE)
20.80%
High
Sector -18.81%|S&P 17.06%
Return on invested capital (ROIC)
17.46%
Fair
Free cash flow margin (FCF)
24.59%
High
Profit-to-cash conversion (FCF conversion)
0.81x
High
Margin stability
21.6 pts
Very uneven
Revenue to net income
Growth
2.9/10Revenue up 10.4% over 1 year, 14.2% a year over 5, EPS 8.3% a year over 5.
Revenue (trailing 12 months)
13.0Md USD
Revenue growth (1y)
10.39%
Solid
Revenue growth (3y)
38.02%
Solid
EPS growth (1y)
-39.08%
Declining
EPS CAGR (5y)
8.28%
Fair
EPS revisions (3 months)
-4.89%
Revised down
Valuation
1.9/10P/E 35.0x, forward P/E 37.8x, EV/EBITDA 29.0x, PEG 4.22. The multiple sits in the 98th percentile of its own 5-year history.
P/E (TTM)
35.0x
Fair
Sector 29.6x|S&P 23.6x
Forward P/E
37.8x
Expensive
EV / EBITDA
29.0x
Expensive
Sector 17.2x|S&P 15.5x
PEG
4.22
Very expensive
Sector 0.88|S&P 0.91
Fair value (reverse DCF)
358.26 USD
Deeply overvalued
P/E vs its own 5-year history
among the 2% highest valuations
At its historical high
Market cap
138Md USD
Financial strength
8.0/10Cash covers 97.4% of the debt, net debt/EBITDA -0.9x.
Net debt / EBITDA
-0.9x
Net cash
Gearing (net debt / equity)
0.79%
Stretched
Cash
6.3Md USD
Cash / market cap
4.58%
Tight
Cash / total debt
97.44%
Very solid
Interest coverage
93.0x
Very solid
Net debt
166M USD
Equity
20.9Md USD
Closed daily candles, 2 years
Last close on November 10, 2026: 547.89 USD
- MM20529.80
- MM50523.05
- MM200482.34
- RSI 1457.8
Top panel: closed candles, 20, 50 and 200-day moving averages, with volume in grey. Bottom panel: 14-day RSI with dashed 30 and 70 levels.
200-day average slope, 1 month
+1.52%
200-day average slope, 3 months
+5.73%
50-day average slope, 1 month
+0.38%
Price structure
higher-low
Bullish RSI divergence
No
20-day volatility
1.99 % per day
Volatility change
+19.16%
Forecasts by fiscal year
| Fiscal year | EPS | Normalised EPS | Revenue | EBITDA | Net income |
|---|---|---|---|---|---|
| 2026 | 14.36 (15) | 18.12 (25) | 13 257 (27) | 5 663 (6) | 3 659 (15) |
| 2027 | 17.38 (16) | 19.95 (25) | 14 653 (25) | 6 290 (6) | 4 519 (16) |
Amounts in millions of USD, EPS in USD per share. In brackets, the number of analysts. Consensus as of November 12, 2026.
Same sub-industry: 416 companies behind the medians.
| # | Company | Code | Country | Overall / 10 | Fundamentals / 10 | Mkt cap | P/E | Net margin | Revenue growth | ROIC | Net debt / EBITDA | FCF yield | 1-year perf. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ARGX | 6.6 | 6.1 | 60.3Md USD | 38.9x | 32.8 % | 81.8 % | 23.3 % | -4.1x | 1.8 % | 16.9 % | ||
| 2 | ONC | 6.6 | 6.6 | 47.2Md USD | 53.2x | 13.9 % | 34.0 % | 14.5 % | -4.4x | 3.1 % | 25.7 % | ||
| 3 | REGN | 6.4 | 6.1 | 99.2Md USD | 21.2x | 28.5 % | 36.3 % | 13.9 % | -1.3x | 3.9 % | 47.3 % | ||
| 4 | ABBV | 6.1 | 5.0 | 521Md USD | 50.8x | 15.6 % | 10.3 % | 16.1 % | 2.2x | 3.6 % | 34.7 % | ||
| 5 | VRTX | 5.7 | 4.1 | 138Md USD | 35.0x | 30.5 % | 10.4 % | 17.5 % | -0.9x | 2.3 % | 26.5 % | ||
| 6 | AMGN | 5.5 | 5.3 | 253Md USD | 27.2x | 24.1 % | 8.1 % | 14.7 % | 2.9x | 3.8 % | 44.7 % | ||
| 7 | CSL | 4.6 | 3.7 | 65.9Md USD | Not meaningful (loss) | -15.6 % | -2.8 % | -8.9 % | 1.8x | 4.3 % | 14.8 % | ||
| 8 | GILD | 4.2 | 2.9 | 211Md USD | Not meaningful (loss) | -12.4 % | 6.7 % | -9.6 % | 1.1x | 6.5 % | 43.1 % | ||
| 9 | MRNA | 3.3 | 1.3 | 101Md USD | Not meaningful (loss) | -110.5 % | 29.2 % | -26.5 % | 0.4x | -2.0 % | 896.8 % |
